Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Barbara Holzer, Broadcast Manager
w. (202) 588-7716
bholzer@citizen.org

Karilyn Gower, Press Officer
w. (202) 588-7779
kgower@citizen.org

Symone Sanders, Communications Officer, Global Trade Watch division
w. (202) 454-5108
ssanders@citizen.org

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog
Facebook/publiccitizen

Follow us on Twitter

 

April 17, 2013

FDA Should Reject Dangerous Lung Medicine, Public Citizen Tells Advisory Committee

Fluticasone/Vilanterol Combination Therapy, Studied in a Series of Unethical Clinical Trials, Is Risky, Provides Little Added Benefit to Patients

WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) should not approve the proposed combination therapy fluticasone/vilanterol (proposed trade name: Breo Ellipta) for the treatment of chronic obstructive pulmonary disease (COPD) because it is not substantially more effective than the single ingredient vilanterol but leads to an increase in several serious side effects, Public Citizen said today in testimony to the FDA’s Pulmonary and Allergy Diseases Advisory Committee.

COPD is a group of progressive, irreversible lung diseases including emphysema and chronic bronchitis, caused in most cases by smoking. Fluticasone/vilanterol is the latest in a long line of combination therapies developed to treat the disease that consist of an inhaled corticosteroid (ICS) and a medicine known as a long-acting beta agonist (LABA), which opens up constricted airways.

Four clinical trials were designed to test the combination of fluticasone/vilanterol therapy against vilanterol alone for up to one year. The combination of fluticasone/vilanterol did not provide any substantial benefit over vilanterol in improving COPD symptoms, but did lead to an increased number of serious side effects compared with subjects getting only vilanterol, including bone fractures and infections such as pneumonia.

Public Citizen also testified that two of the four pivotal trials were unethical because investigators withheld effective, standard treatments, including other ICS/LABA therapies, for almost six months, from hundreds of subjects with severe COPD, instead giving some placebo pills and others substandard care with inhaled steroids alone. Such trials are permitted, and unfortunately not uncommon, under the FDA’s current regulatory system governing drug approvals.

“This new combination therapy, never arguably a breakthrough drug to begin with, was conclusively shown to be more risky, and not substantially more effective, than vilanterol alone in the pivotal trials,” said Dr. Sammy Almashat, researcher with Public Citizen’s Health Research Group. “And that two of the trials that denied effective treatments to hundreds of severely ill patients were even allowed to go forward – without objection from either the FDA or local institutional review boards – is a sad testament to the lack of adequate protections that exist for trial subjects today.”

Read today’s testimony.

A minor edit was made, changing "no more" to "not substantially more" in the first paragraph on April 22, 2013.

 

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.